Cheryl McAlpine

772 total citations
12 papers, 254 citations indexed

About

Cheryl McAlpine is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Cheryl McAlpine has authored 12 papers receiving a total of 254 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Immunology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Cheryl McAlpine's work include CAR-T cell therapy research (9 papers), Immunotherapy and Immune Responses (8 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Cheryl McAlpine is often cited by papers focused on CAR-T cell therapy research (9 papers), Immunotherapy and Immune Responses (8 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Cheryl McAlpine collaborates with scholars based in United States, United Kingdom and Canada. Cheryl McAlpine's co-authors include Pippa Corrie, Omid Hamid, Neil Steven, Jeffrey R. Infante, Mario Sznol, Alexander N. Shoushtari, Mark R. Middleton, Avinash Gupta, Jacob Hurst and T.R. Jeffry Evans and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Cheryl McAlpine

12 papers receiving 239 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cheryl McAlpine United States	6	154	145	107	73	56	12	254
Revashnee Naidoo United States	4	123 0.8×	111 0.8×	73 0.7×	47 0.6×	40 0.7×	7	181
Timothy Isaacs Australia	10	65 0.4×	59 0.4×	297 2.8×	111 1.5×	85 1.5×	19	381
Jennifer Arnold United States	7	99 0.6×	248 1.7×	23 0.2×	83 1.1×	40 0.7×	10	354
Torleif Tollefsrud Gjølberg Norway	7	43 0.3×	27 0.2×	33 0.3×	101 1.4×	78 1.4×	12	209
Adriana Buskin United Kingdom	8	20 0.1×	43 0.3×	55 0.5×	189 2.6×	20 0.4×	11	258
Breanna M. Bates United States	6	62 0.4×	146 1.0×	20 0.2×	81 1.1×	4 0.1×	8	198
Julia Beutel Germany	10	35 0.2×	28 0.2×	334 3.1×	85 1.2×	244 4.4×	17	377
Lori K. Weimer United States	8	145 0.9×	8 0.1×	90 0.8×	45 0.6×	102 1.8×	10	394
Rachel L. Davis United States	3	140 0.9×	123 0.8×	5 0.0×	28 0.4×	10 0.2×	5	197
Francesco Russo Italy	7	32 0.2×	17 0.1×	16 0.1×	176 2.4×	16 0.3×	7	200

Countries citing papers authored by Cheryl McAlpine

Since Specialization

Citations

This map shows the geographic impact of Cheryl McAlpine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheryl McAlpine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheryl McAlpine more than expected).

Fields of papers citing papers by Cheryl McAlpine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheryl McAlpine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheryl McAlpine. The network helps show where Cheryl McAlpine may publish in the future.

Co-authorship network of co-authors of Cheryl McAlpine

This figure shows the co-authorship network connecting the top 25 collaborators of Cheryl McAlpine. A scholar is included among the top collaborators of Cheryl McAlpine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheryl McAlpine. Cheryl McAlpine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

D’Angelo, Sandra P., Kristen N. Ganjoo, Jean‐Yves Blay, et al.. (2023). The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.. Journal of Clinical Oncology. 41(16_suppl). e14531–e14531. 1 indexed citations

Tine, Brian Andrew Van, Kristen N. Ganjoo, Jean‐Yves Blay, et al.. (2023). The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11563–11563. 8 indexed citations

Wang, Tianjiao, Jean‐Marc Navenot, Stavros Rafail, et al.. (2022). Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients. Cancer Research. 82(12_Supplement). LB001–LB001. 2 indexed citations

Schmidt, Emily M., Katerina Mardilovich, Natalie Bath, et al.. (2021). 373 Enhancement of TCR-engineered T-cells targeting MAGE-A4 antigen by co-expression of CD8α and inhibition of AKT signaling during ex vivo T-cell expansion. Regular and Young Investigator Award Abstracts. A401–A401. 3 indexed citations

Welsh, James, Hampartsoum B. Barsoumian, Jane P. F. Bai, et al.. (2021). 376 Radiation sub-study to characterize safety and tolerability of low-dose radiation in combination with afami-cel in patients with advanced cancers (NCT03132922). SHILAP Revista de lepidopterología. A407–A407. 2 indexed citations

Middleton, Mark R., Cheryl McAlpine, Victoria K. Woodcock, et al.. (2020). Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. Clinical Cancer Research. 26(22). 5869–5878. 165 indexed citations

Middleton, Mark R., Neil Steven, Jeffrey R. Infante, et al.. (2019). Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma.. Journal of Clinical Oncology. 37(15_suppl). 9523–9523. 1 indexed citations

Carvajal, Richard D., Joseph J. Sacco, Paul Nathan, et al.. (2017). Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector IMCgp100 in advanced uveal melanoma. Investigative Ophthalmology & Visual Science. 59(9). 3622–3622. 5 indexed citations

Sato, Takami, Paul Nathan, Leonel F. Hernandez‐Aya, et al.. (2017). Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.. Journal of Clinical Oncology. 35(15_suppl). 9531–9531. 16 indexed citations

10.

Middleton, Mark R., Neil Steven, Jeffrey R. Infante, et al.. (2016). Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma.. Journal of Clinical Oncology. 34(15_suppl). 3016–3016. 37 indexed citations

11.

Kent, Toby, et al.. (2007). G-protein-coupled receptor heterodimerization: assay technologies to clinical significance.. PubMed. 10(5). 580–9. 13 indexed citations

12.

Wyper, D., Cheryl McAlpine, Khalil Jawad, & B. Jennett. (1976). Effects of a carbonic anhydrase inhibitor on cerebral blood flow in geriatric patients.. Journal of Neurology Neurosurgery & Psychiatry. 39(9). 885–889. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact